SynCardia Named "Arizona Bioscience Company of the Year"
Total Artificial Heart Manufacturer Honored by Arizona BioIndustry Association for "Doing the Most to Transform the World during the Last 12 Months"
“The Arizona Bioscience Company of the Year Award recognizes the for-profit bioscience company whose Arizona-based operations did the most to transform the world during the last 12 months,” said AZBio CEO Joan Koerber-Walker. “SynCardia makes it possible for patients awaiting donor hearts to not only survive the wait but also to do so with flexibility and mobility, a feat of biomedical engineering that is world-changing for these patients.”
SynCardia designed, developed, and introduced the Freedom® portable driver, the world’s first wearable power supply for the SynCardia temporary Total Artificial Heart. For the first time in U.S. history, stable patients without human hearts are being discharged from the hospital to wait for a matching donor heart at home using the Freedom portable driver to power their Total Artificial Hearts. Weighing 13.5 pounds, the Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
Prior to the development of the Freedom driver, U.S. Total Artificial Heart patients were confined to the hospital for months, sometimes years, while they waited for a heart transplant because the only FDA-approved driver for powering the Total Artificial Heart is hospital-based “Big Blue” which weighs 418 pounds.
Life for a stable Total Artificial Heart patient confined to the hospital is emotionally, physically and financially draining for them, their family and the hospital. As wait times for a heart transplant continue to lengthen, the ability to discharge stable patients home is critical for both the patient and the hospital. Recovery at home improves patient quality of life while eliminating most in-hospital costs for this portion of patient care.
The other two finalists for the award were Calimmune, Inc., which is developing innovative cell-based therapies for treating HIV, and VisionGate, which has developed an automated 3D cell imaging platform to help detect lung cancer sooner.
AZBio is the state affiliate of the Biotechnology Industry Organization (BIO), the preeminent national association for biotechnology companies, and of AdvaMed, the largest association representing manufacturers of medical devices, diagnostic products and medical information systems.
SynCardia Systems Inc
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Similar to a heart transplant, the SynCardia temporary Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications.
Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles.
SynCardia Ranked #20 Among World's 50 Most Innovative Companies:
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the world's 50 Most Innovative Companies for "giving mobility to artificial heart recipients." Weighing 13.5 lbs, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
For additional information, please visit: http://www.syncardia.com
Press releases you might also be interested in
Weitere Informationen zum Thema "Medical Technology":
Künstliche Intelligenz sorgt für mehr Transparenz
Eine intransparente Personalpolitik hätte durch den Einsatz von Künstlicher Intelligenz (KI) kaum noch eine Chance, meint etwa ein Drittel aller Führungskräfte. Das zeigt eine aktuelle Studie von Pegasystems.Weiterlesen